Stock Analysis

Medy-Tox And Two Insider-Favored Growth Stocks To Watch

Published

As global markets navigate a landscape marked by central banks adjusting interest rates and mixed performances across major indices, the technology-heavy Nasdaq Composite has stood out by reaching record highs. This environment highlights the potential of growth stocks, particularly those with high insider ownership, as insiders often have unique insights into their companies' prospects. In this context, Medy-Tox and two other growth stocks with significant insider stakes present intriguing opportunities for investors to watch.

Top 10 Growth Companies With High Insider Ownership

NameInsider OwnershipEarnings Growth
SKS Technologies Group (ASX:SKS)27%24.8%
Propel Holdings (TSX:PRL)36.9%37.6%
On Holding (NYSE:ONON)19.1%29.4%
Medley (TSE:4480)34%31.7%
Pharma Mar (BME:PHM)11.8%56.2%
CD Projekt (WSE:CDR)29.7%27%
Plenti Group (ASX:PLT)12.8%120.1%
EHang Holdings (NasdaqGM:EH)32.8%81.5%
Credo Technology Group Holding (NasdaqGS:CRDO)13.4%66.3%
Elliptic Laboratories (OB:ELABS)26.8%111.4%

Click here to see the full list of 1524 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Medy-Tox (KOSDAQ:A086900)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Medy-Tox Inc. is a South Korean biopharmaceutical company with a market cap of approximately ₩850.84 billion.

Operations: The company's revenue primarily comes from its biotechnology segment, generating approximately ₩241.45 billion.

Insider Ownership: 19.8%

Medy-Tox is experiencing significant earnings growth, forecasted at 63.3% annually, outpacing the Korean market's 12.6%. Its revenue growth projection of 14.2% also surpasses the market average. Despite a low future return on equity of 12%, the stock trades at a substantial discount to its fair value estimate and below analyst price targets, suggesting potential upside. Recent share buyback programs aim to stabilize prices and enhance shareholder value amid improving financial performance.

KOSDAQ:A086900 Earnings and Revenue Growth as at Dec 2024

Vobile Group (SEHK:3738)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vobile Group Limited is an investment holding company that offers software as a service for digital content asset protection and transactions across the United States, Japan, Mainland China, and internationally, with a market cap of HK$7.72 billion.

Operations: The company generates revenue primarily from its SaaS offering, amounting to HK$2.18 billion.

Insider Ownership: 23.1%

Vobile Group is poised for substantial earnings growth, forecasted at 63.3% annually, significantly outpacing the Hong Kong market's 11.6%. Revenue growth is expected at 18.1% per year, exceeding the market average of 7.8%. Recent executive changes and a private placement of HK$78 million in convertible bonds underscore strategic shifts. Despite past shareholder dilution and volatile share prices, ongoing buybacks aim to enhance net asset value per share and stabilize financial performance.

SEHK:3738 Earnings and Revenue Growth as at Dec 2024

Gourmet Master (TWSE:2723)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Gourmet Master Co. Ltd., with a market cap of NT$18.09 billion, operates and franchises chain stores across China, Taiwan, the United States, and internationally through its subsidiaries.

Operations: The company generates revenue primarily from its restaurants segment, which amounts to NT$19.08 billion.

Insider Ownership: 18.6%

Gourmet Master is trading significantly below its estimated fair value, presenting a potential opportunity despite recent financial declines. Earnings are forecast to grow at 39.14% annually, surpassing the Taiwan market's average growth rate. However, profit margins have decreased from last year and revenue growth is modest at 4.7% per year. The company lacks recent insider trading activity and faces challenges with dividend sustainability as earnings do not adequately cover payouts.

TWSE:2723 Earnings and Revenue Growth as at Dec 2024

Seize The Opportunity

Curious About Other Options?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com